ME01517B - Prevencija infekcije hiv-om s tmc278 - Google Patents

Prevencija infekcije hiv-om s tmc278

Info

Publication number
ME01517B
ME01517B MEP-2013-30A MEP3013A ME01517B ME 01517 B ME01517 B ME 01517B ME P3013 A MEP3013 A ME P3013A ME 01517 B ME01517 B ME 01517B
Authority
ME
Montenegro
Prior art keywords
tmc278
prevention
hiv
infection
hiv infection
Prior art date
Application number
MEP-2013-30A
Other languages
English (en)
Inventor
Paulus Joannes Lewi
Jan Heeres
Lieven Elvire Colette Baert
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of ME01517B publication Critical patent/ME01517B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ovaj pronalazak odnosi se na upotrebu parenteralne formulacije koja sadrži NNRTI TMC278 za dugotrajnu prevenciju infekcije HIV-om za subjekt koji je izložen riziku da bude inficiran HIV-om, što obuhvata intermitentnu primenu (primenu s prekidima) navedene formulacije u dugim vremenskim intervalima
MEP-2013-30A 2005-04-04 2006-04-04 Prevencija infekcije hiv-om s tmc278 ME01517B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102616 2005-04-04
EP06725539A EP1881848B1 (en) 2005-04-04 2006-04-04 Prevention of hiv-infection with tmc278
PCT/EP2006/061303 WO2006106103A2 (en) 2005-04-04 2006-04-04 Prevention of hiv- infection with tmc278

Publications (1)

Publication Number Publication Date
ME01517B true ME01517B (me) 2014-04-20

Family

ID=34939113

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-30A ME01517B (me) 2005-04-04 2006-04-04 Prevencija infekcije hiv-om s tmc278

Country Status (29)

Country Link
US (6) US20080194601A1 (me)
EP (1) EP1881848B1 (me)
JP (2) JP5632579B2 (me)
KR (1) KR101360851B1 (me)
CN (2) CN103860560A (me)
AP (1) AP2617A (me)
AR (1) AR053571A1 (me)
AU (1) AU2006231585B2 (me)
BR (1) BRPI0607649B8 (me)
CA (1) CA2602231C (me)
CY (1) CY1113950T1 (me)
DK (1) DK1881848T3 (me)
EA (1) EA011420B1 (me)
ES (1) ES2402864T3 (me)
HK (2) HK1117039A1 (me)
HR (1) HRP20130296T1 (me)
IL (1) IL184744A (me)
ME (1) ME01517B (me)
MX (1) MX2007012277A (me)
MY (1) MY150091A (me)
NZ (1) NZ556659A (me)
PL (1) PL1881848T3 (me)
PT (1) PT1881848E (me)
RS (1) RS52724B (me)
SI (1) SI1881848T1 (me)
TW (2) TW201414495A (me)
UA (1) UA90124C2 (me)
WO (1) WO2006106103A2 (me)
ZA (1) ZA200708454B (me)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CN103877091A (zh) * 2006-01-20 2014-06-25 泰博特克药品有限公司 用tcm278对hiv感染进行的长期治疗
DK2040671T3 (en) 2006-06-23 2018-05-07 Janssen Sciences Ireland Uc AURAL SUSPENSIONS OF TMC278
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
US20110256206A1 (en) 2008-12-24 2011-10-20 Schachter Deborah M Implantable devices for treating hiv
SG181759A1 (en) * 2009-12-21 2012-07-30 Janssen R & D Ireland Degradable removable implant for the sustained release of an active compound
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
PE20151326A1 (es) 2012-12-14 2015-10-12 Glaxosmithkline Llc Composiciones farmaceuticas que comprenden derivados de betulina
AU2015323321A1 (en) 2014-09-26 2017-04-13 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
HUP0302631A2 (hu) 2000-03-30 2003-11-28 Bristol-Myers Squibb Co. Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2004043433A2 (en) 2002-11-08 2004-05-27 Glaxo Group Limited Pharmaceutical antiviral compositions
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
WO2004073703A1 (en) 2003-02-21 2004-09-02 Tripep Ab Glycinamide derivative for inhibiting hiv replication
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CN103877091A (zh) * 2006-01-20 2014-06-25 泰博特克药品有限公司 用tcm278对hiv感染进行的长期治疗
DK2040671T3 (en) * 2006-06-23 2018-05-07 Janssen Sciences Ireland Uc AURAL SUSPENSIONS OF TMC278

Also Published As

Publication number Publication date
NZ556659A (en) 2012-03-30
TW201414495A (zh) 2014-04-16
US20110077261A1 (en) 2011-03-31
US20160296519A1 (en) 2016-10-13
CA2602231C (en) 2014-03-25
US20080194601A1 (en) 2008-08-14
BRPI0607649A2 (pt) 2009-09-22
US20220071997A1 (en) 2022-03-10
US10765674B2 (en) 2020-09-08
MX2007012277A (es) 2007-10-17
PT1881848E (pt) 2013-04-15
AU2006231585B2 (en) 2012-02-02
IL184744A0 (en) 2007-12-03
AU2006231585A1 (en) 2006-10-12
CN103860560A (zh) 2014-06-18
WO2006106103A3 (en) 2007-06-07
KR20080009051A (ko) 2008-01-24
ZA200708454B (en) 2009-03-25
BRPI0607649B8 (pt) 2021-05-25
ES2402864T3 (es) 2013-05-09
JP2013079275A (ja) 2013-05-02
CA2602231A1 (en) 2006-10-12
US20160151276A1 (en) 2016-06-02
DK1881848T3 (da) 2013-04-15
BRPI0607649B1 (pt) 2019-08-06
EP1881848A2 (en) 2008-01-30
JP2008534651A (ja) 2008-08-28
EA011420B1 (ru) 2009-02-27
TWI457136B (zh) 2014-10-21
AR053571A1 (es) 2007-05-09
CN101155599A (zh) 2008-04-02
KR101360851B1 (ko) 2014-02-11
AP2007004178A0 (en) 2007-10-31
HK1198936A1 (en) 2015-06-19
US20200397783A1 (en) 2020-12-24
SI1881848T1 (sl) 2013-05-31
CY1113950T1 (el) 2016-07-27
HRP20130296T1 (hr) 2013-04-30
PL1881848T3 (pl) 2013-06-28
EA200702169A1 (ru) 2008-02-28
JP5632579B2 (ja) 2014-11-26
MY150091A (en) 2013-11-29
HK1117039A1 (en) 2009-01-09
EP1881848B1 (en) 2013-01-16
RS52724B (en) 2013-08-30
WO2006106103A2 (en) 2006-10-12
UA90124C2 (ru) 2010-04-12
TW200709818A (en) 2007-03-16
AP2617A (en) 2013-03-18
IL184744A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
ME01517B (me) Prevencija infekcije hiv-om s tmc278
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
HRP20110451T1 (hr) Upotreba izotiocijanata kao sredstva protiv mieloma
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
CR8246A (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
ATE517874T1 (de) Pyrimidinone als modulatoren von caseinkinase ii (ck2)
EA201070519A1 (ru) Соединения тропана
NO20090175L (no) Stabile laquinimod sammensetninger
PA8649401A1 (es) Analogos de anilino-pirimidina
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
CL2011001413A1 (es) Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana.
ECSP11010765A (es) NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACIÓN, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDORES DE MET
PH12015502684A1 (en) New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
EA201290229A1 (ru) Производные спиролактама и их применение
AR069781A1 (es) Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
UY29133A1 (es) Amidas conteniendo (!!2-tert-butil-1-(tetrahidro-2h-piran-4-ilmetil)-1h-bencimidazol-5-!!) (metil)amino!sulfonilo) como sustituyente. procedimiento de preparacion, composiciones que lo contienen y aplicaciones
BRPI0411820B8 (pt) composição farmacêutica para administração parenteral, e seus usos
MA33055B1 (fr) Nouvelle combinaison de principes actifs contenant un anti-inflammatoire non steroidien et un derive de colchicoside